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Abstract 35 
 36 
Background  37 
Patient preferences for pharmaceutical treatment of osteoarthritis have been 38 
investigated using Fonjoint Analysis. S tudies have identified the importance of side 39 
effects in determining preferences, but noted that methodological limitations 40 
precluded further investigation of additional attributes such as hepatic and kidney 41 
toxicity. 42 
 43 
Objective 44 
Following on from a feasibility study of adaptive choice-based conjoint (AFBF) 45 
analysis, the aim of this study was to evaluate eight medication attributes for the 46 
pharmaceutical treatment of osteoarthritis (OA). 47 
 48 
S etting and Participants  49 
E leven participants were recruited from members of a R esearch Users’ Group 50 
(R UG) who had been diagnosed with osteoarthritis. R UG members individually 51 
complete the AFBF  task.  52 
 53 
Main outcome measures  54 
The relative importance of each attribute and the utilities (part-worth) of each level 55 
of each attribute we estimated using AFBF  built-in Hierarchical Bayes (HB). 56 
 57 
R esults  58 
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The combined relative importance of the four risk side-effect attributes when 59 
selecting osteoarthritis medication (kidney and liver side effects, heart attack and 60 
stroke side effects, stomach side effects, and addiction) was 66% while the 61 
effectiveness attribute accounted for 8% of the relative importance of the medication 62 
decision. 63 
 64 
Fonclusions 65 
In this study, the gap between relative importance of four side-effect attributes and 66 
expected benefit was 66% vs 8%. These preliminary findings indicate that OA 67 
patients are most concerned with the avoidance of adverse events and that there is 68 
a threshold above which expected benefit has little impact on patients’ medication 69 
preferences. The study highlights methodological features of AFBF that may be 70 
useful more generally in health services research. Our results must be interpreted 71 
in conjunction with the study limitations.  72 
 73 
R unning title: Preferences for treatment of osteoarthritis  74 
 75 
K eywords: Adaptive choice-based conjoint analysis, osteoarthritis, pharmaceutical 76 
treatment, patient preferences. 77 
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Introduction 79 
 80 
Medication preference may be influenced by a wide range of factors including the 81 
efficacy in reducing serious outcomes of disease, and, especially for a non-fatal but 82 
long-term, symptomatic disease such as osteoarthritis (OA), in dealing with 83 
important but less serious symptoms such as pain or stiffness in the joints L1]. S uch 84 
clinical benefits may be judged alongside practical characteristics of different 85 
medications, such as dosage, frequency and nature of delivery of the medication 86 
L2,3]. 87 
 88 
Against the benefits of treatment and the practical features of the medication will 89 
also be weighed the potential side effects of taking the medication. This will be 90 
particularly so when the condition itself (OA) is troublesome in its effects for most 91 
people (pain and restricted activity) rather than serious in the sense of life-92 
threatening disease. 93 
 94 
OA medications are associated with several side effects such as gastric ulcer, liver 95 
and kidney toxicity and cardiovascular side effects. The prevalence of these side 96 
effects varies between medications. F or example, although, gastrointestinal side 97 
effects of NS AIGs are well documented as common side effects, others such as 98 
cardiovascular and hepatic side effects are less common. Heart failure occurs in 99 
approximately 1 per 100 patients using NS AIGs L4] and hepatotoxicity occurs in 1.7 100 
per 100 000 individuals using NS AIGs L5]. The annual incidence of NS AIG-related 101 
clinical upper GI events is estimated to be between 2.5% to 4.5%, with the annual 102 
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incidence of serious complications (severe bleeding, perforation, and obstruction) 103 
about 1% to 1.5%. L6] 104 
 105 
The degree of joint aches, the degree of physical mobility and the risk of 106 
experiencing serious side effects from OA treatment are important attributes in 107 
influencing OA treatment preferences L7]. Of particular concern are serious side 108 
effects, even when these are associated with a low prevalence rate L7].  109 
 110 
In a study by Fraenkel and colleagues L1] examining seven attributes in relation to 111 
the pharmaceutical treatment of knee OA, the relative importance of each attribute 112 
was expressed in percentage terms. Their results suggested that avoidance of side 113 
effects, especially those with more serious drug-related toxic effects, is central to 114 
patients’ treatment preferences even if this involves foregoing treatment. The 115 
method used by F raenkel and colleagues L1] was adaptive conjoint analysis (AFA). 116 
AFA involves participants’ rating their preference between two sets of attribute 117 
configurations L8] Fompared to paper based rating methods that used pre-118 
determined choice comparison sets, AFA choice sets adapt at each stage based on 119 
the individual’s ratings at earlier stages of the process. 120 
 121 
F raenkel and colleagues L9] indicated that the range of side effects that they were 122 
able to study was limited, because the inclusion of more attributes would have 123 
created an overly complicated AFA task. They hypothesized that the inclusion of 124 
additional adverse effects (such as renal toxicity) would lead to greater avoidance 125 
of drugs with side effects and that therefore patients would choose other treatment 126 
options such as exercise. 127 
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 128 
Another approach has been used to investigate patient preferences for attributes 129 
associated with the efficacy and side effects for treatment in OA is choice-based 130 
conjoint (FBF) analysis L10]. Fhoice based methods have become more popular 131 
than rating based methods as a way of eliciting patient preferences L8]. The main 132 
characteristic distinguishing from AFA is that instead of rating or ranking individual 133 
attributes, respondents are shown sets of treatment attributes and asked to indicate 134 
which set they would prefer L10]. FBF has been recently used to investigate patient 135 
preferences for potential disease-modifying drugs for osteoarthritis (GMOAGs) L
11
]. 136 
This study involved four attributes, each with three levels; 1) route of administration, 137 
2) expected benefit, 3) risk of drug toxicity 4) cost L11]. In this study potential benefit 138 
was the most influential factor (39.4% of the relative importance followed by risk of 139 
side effects (26.9%), cost (24.9%), and route of administration (8.8%).   140 
 141 
As part of the preparation for the current study, the feasibility of adaptive choice-142 
based conjoint (AFBF) analysis was evaluated L12]. AFBF contains elements of 143 
AFA and FBF . AFBF  features adaptation of scenarios based on a respondent’s 144 
earlier choices (from AFA), and the use of choice rather than ranking of scenarios 145 
(from FBF). The feasibility study reported on the steps taken to develop an AFBF  146 
task that enabled participants to evaluate a wide range of medication attributes for 147 
the treatment of OA. The results showed that older patients (who predominate 148 
among patients with OA), even without computer experience or computer literacy, 149 
can use a computer-based adaptive choice-based questionnaire to produce 150 
quantitative estimates of the relative importance of the different attributes 151 
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preferences. Getailed analyses of three individuals’ medical priorities using this 152 
method are reported elsewhere L13]. 153 
 154 
The aim of the present study was to evaluate the use of AFBF in eliciting treatment 155 
preferences by determining the relative importance of eight attributes in selecting 156 
pharmaceutical treatment of OA. While the present study reports on a small group 157 
of participants, and is not claimed to be representative of OA patients in general, the 158 
intention is to evaluate the use of AFBF  with a larger range of side effect attributes 159 
than previous studies. 160 
 161 
Method 162 
 163 
Participants  164 
 165 
Participants were drawn from members of a R esearch Users’ Group (R UG) who had 166 
been diagnosed with OA and had reported one or more of hip, knee, hand and foot 167 
joint pain in past 12 months. E leven R UG members were recruited. Participants 168 
were OA patients age 50 or above. Having established the feasibility and practicality 169 
of the methods, we proceed to conduct a pilot study to investigate the relative 170 
importance and utilities of the attributes, while acknowledging that the sample would 171 
be too small to extrapolate these to all patients with OA. 172 
 173 
 174 
E thical statement 175 
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All participants in this project were members of the extended Patient and Public 176 
Involvement (PPI) group of the Arthritis R esearch UK Primary Fare F entre at Keele 177 
University. These members had signed an agreement, which permits the Fentre to 178 
use their expertise in the development of research. This project was approved by 179 
the PPI team of the Arthritis R esearch UK Primary F are Fentre at Keele University 180 
and complied with Keele University guidelines for the storage of sensitive and 181 
confidential data on laptops. 182 
 183 
Gata collection and analysis 184 
 185 
The data were collected from the eleven participants in the computer laboratory at 186 
the Arthritis R esearch UK Primary Fare Fentre at Keele University over two days in 187 
2012. A Hierarchical Bayes (HB) model was used to estimate: a) the relative 188 
importance of each attribute, and b) utilities of each level of each attribute. 189 
 190 
R elative importance of each attribute: The relative importance of all attributes adds 191 
up to 100%. A higher relative importance represents a greater impact of the attribute 192 
concerned on patients’ preferences. Relative importance is ratio-scaled and relative, 193 
such that an attribute with relative importance of 20% is twice as important as an 194 
attribute with relative importance of 10% within L14]. 195 
 196 
Utilities (part-worth) of each level of each attribute: The order of the levels in each 197 
attribute is reported using utilities. Utilities are interval data and scaled within each 198 
attribute. The utilities of levels in each attribute are scaled to sum to “0”. The utility 199 
for each level is a number that represents the weight that respondents put on that 200 
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particular level in context with other levels within the same attribute. The level with 201 
the highest utility is the most favourable. Utilities are estimated through the 202 
maximum likelihood of each level (14). 203 
 204 
R esults 205 
 206 
Participants’ characteristics 207 
 208 
There were eleven participants (4 male and 7 female) with OA in the hips, knees, 209 
shoulders, hands, ankles, and/or spine. All participants were over 50 years of age; 210 
the modal age category was 60-69 years (see table 1 for frequency of age groups). 211 
 The majority of patients (72.8%) had had OA for over 5 years. All participants 212 
reported that joint pain affected their normal life; 81.8% reported that effect to be 213 
moderate to extreme. 214 
 215 
Table 1 216 
 217 
The participants reported using paracetamol (81.8%), NS AIGs and FOX-2 inhibitors 218 
(81.8%), opioids (63.6%), and glucosamine (63.6%) for the management of OA. 219 
None of the participants reported previous or current use of capsaicin. 220 
 221 
The relative importance of attributes  222 
 223 
Table 2 shows the relative importance of each attribute, representing the impact of 224 
that particular attribute on patients’ preferences. The most important attribute was 225 
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“risk of kidney and liver side effects”, which accounted for 22.2% of the relative 226 
importance. The second most important attribute was “risk of heart attacks and 227 
strokes” with 17.4%. The least important attributes were “expected benefit” (7.5%) 228 
and “way of taking the medication” (6.9%). 229 
 230 
Table 2 231 
 232 
Utilities of levels of attributes 233 
F igure 1 shows the mean utility for each level. These results suggest that the 234 
preferred levels for each attribute are a prescription drug, taken orally when needed, 235 
with 50% benefit expected, and no risk of addiction, stomach ulcer, kidney or liver 236 
impairment, or heart attacks & strokes. Participants were avoiding medications that 237 
are to be taken frequently (two or more times a day) and favouring those in the form 238 
of cream/gel rather than taken orally. Furthermore, participants were avoiding 239 
medications that are purchased via the internet. 240 
 241 
F igure 1 242 
 243 
Giscussion 244 
 245 
This study collected data from eleven patients with established painful OA, all with 246 
experience of using medication for the condition. The study examined their 247 
medication preferences by using an AFBF task involving 28 levels of eight 248 
medication attributes. The aim of the present study was to evaluate the use of AFBF 249 
in eliciting treatment preferences by determining the relative importance of eight 250 
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attributes in selecting pharmaceutical treatments for OA. As the present study had 251 
a small sample size, the generalisability of the results is limited. 252 
 253 
Given this caveat, the results generally support the suggestion by Fraenkel et.al. L1-254 
3] that the inclusion of more serious side effect attributes would elicit a preference 255 
for safer treatment options such as exercise. In the current study the effectiveness 256 
attribute accounted for only 8% of the relative importance of the medication decision 257 
compared to 15% in an earlier study L9]. There was little difference in the utility value 258 
for medication effectiveness (expect 50% or 75% benefit), although the values at 259 
these levels were higher than those at the lowest level (expect 25% benefit). This 260 
finding indicates that there is a threshold above which expected benefit has little 261 
impact on patients’ medication preferences. 262 
 263 
However, the relative importance of these attributes should be interpreted in relation 264 
to all attributes included in the conjoint task. To further evaluate this issue, it would 265 
be necessary to conduct an AFBF study in which different attributes (i.e. with 266 
different combinations of benefit and risk should be administered to the same 267 
sample. Hauber and colleagues L15] used a form of choice-based conjoint (FBF) 268 
analysis to study patients’ willingness to risk adverse events for improved function 269 
and pain control in OA. Their study involved six attributes of which two related to 270 
adverse events. They reported that patients tended to attach greater importance to 271 
eliminating the risks of adverse events than to reducing pain. Thus, the importance 272 
of side effects is also confirmed in a study where fewer attributes related to adverse 273 
events.  274 
 275 
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This study was preceded by a detailed feasibility study to identify attributes and 276 
levels that may influence patients’ preferences regarding pharmaceutical treatment 277 
of osteoarthritis L12, 13]. E ight attributes and 28 levels were identified and 278 
considered to potentially influence patients’ preferences regarding pharmaceutical 279 
treatment of OA. Taken together with the feasibility study, the current findings 280 
indicate that AFBF  is a potentially valid method of evaluating patients’ preferences 281 
for pharmaceutical treatment of OA. It remains to be seen whether more attributes 282 
can be studied and whether this will alter the basic finding that avoidance of side 283 
effects is the major determinant of patients’ preferences regarding pharmaceutical 284 
treatment of osteoarthritis.  285 
 286 
Fonclusion  287 
 288 
This study is the first conjoint analysis study to have included eight attributes related 289 
to patients’ preferences for pharmaceutical treatment of OA, and in addition 290 
including liver, kidney, gastric, heart attacks, stokes, and addiction side effects. This 291 
study addresses the issues raised by Fraenkel and colleagues L9] regarding the 292 
need for conjoint techniques that could include attributes on hepatic and kidney 293 
toxicity. The study extends our understanding of factors influencing patients’ 294 
preferences for pharmaceutical treatment of OA and highlights methodological 295 
features of AFBF  that maybe be useful in health services research. 296 
 297 
 298 
 299 
  300 
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 305 
Table 1 Participant characteristics. 306 
Participants characteristics  Percent 
Age groups 
50-59 
60-69 
Over 69 
 
9.1 
63.6 
27.3 
Y ears with osteoarthritis  
1-2 years 
3-4 years 
More than 5 years 
 
9.1 
18.2 
72.8 
  307 
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Tab le 2. welative importance scores of the eight medication attrib utes for the eleven 308 
participants [a ean ± standard deviation (S5); mean scores sum to 100.] 309 
Attribute (wording from current study)  
R elative importance scores for the
medication attributes (with standard 
deviation) 
S tomach side effects 16.5 ± 5.3 
R isk of kidney and liver side effects 22.2 ± 5.8 
R isk of heart attacks and strokes 17.4 ± 3.6 
R isk of addiction 9.6 ± 8.7 
How much you would expect to benefit 7.5 ± 4.8 
Way of taking medication 6.9 ± 6.7 
Availability 12.7 ± 3.7 
F requency 7.3 ± 4.8 
Total 100 
 310 
  311 
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Figure 1 L egend 312 
 313 
Group utilities for all levels, showing propensity to select medication with indicated 314 
attrib ute/level. 315 
 316 
 317 
